Syngenta collaborates with Ginkgo Bioworks to enable faster launch of innovative biologicals
Syngenta Crop Protection and Ginkgo Bioworks (NYSE: DNA) have announced a new collaboration to accelerate the launch of an innovative biological solution. Ginkgo will develop and optimize a microbial strain to meet Syngenta's productivity targets for a secondary metabolite from their Biologicals pipeline. This collaboration aims to enable cost-effective and large-scale production of the targeted metabolite, significantly expediting Syngenta's go-to-market timeline.
Ginkgo will leverage its Ag Biologicals capabilities, biological knowledge, and machine learning approaches to develop insights from complex data sources and apply them towards diagnosing strain performance limitations and biological feature discovery. This partnership builds on their previous collaboration on next-generation seed technology and underscores the growing importance of biologicals in sustainable agricultural practices.
- Collaboration aims to accelerate the launch of a new biological solution
- Potential for cost-effective and large-scale production of a targeted metabolite
- Leveraging Ginkgo's Ag Biologicals capabilities and machine learning approaches
- Expansion of existing partnership between Syngenta and Ginkgo Bioworks
- None.
Insights
The collaboration between Syngenta and Ginkgo Bioworks represents a noteworthy advancement in the agricultural biotechnology sector. Syngenta's decision to leverage Ginkgo's capabilities in microbial strain engineering is a strategic move aimed at optimizing the production of a key secondary metabolite. This is essential for the development of a pioneering biological solution. The use of machine learning and advanced biological knowledge to streamline strain performance underscores the innovative approach both companies are taking.
Considering the increasing global emphasis on sustainable agricultural practices, this partnership is well-timed. Syngenta's ability to bring new, effective biological solutions to market more rapidly could significantly impact the agricultural industry by providing farmers with more ecologically friendly options. Furthermore, Ginkgo's platform's ability to process complex data for biological feature discovery adds a layer of sophistication and precision to this initiative.
For retail investors, it's important to recognize that such collaborations can lead to substantial long-term benefits despite the inherent risks and uncertainties associated with biotechnological advancements. The focus on sustainable solutions aligns with global trends, potentially positioning Syngenta as a leader in this space.
From a market perspective, this collaboration could have significant implications for both Syngenta and Ginkgo Bioworks. By accelerating the launch of innovative biological solutions, Syngenta can enhance its competitive position in the agri-biotech market. The ability to bring products to market faster could translate to increased market share and revenue growth. For Ginkgo, this partnership not only strengthens its market positioning but also showcases its technological prowess in practical applications, potentially attracting more customers and partners.
Short-term, the market may react positively to the announcement due to the potential for quicker revenue realization. However, it’s critical to consider the long-term implications. The success of the collaboration hinges on the ability to meet productivity targets and achieve commercial viability. Investors should watch for updates on milestones and performance indicators related to the microbial strain development.
Another aspect worth noting is the sustainability angle. As environmental concerns become more prominent, companies offering solutions that contribute to sustainable agriculture are likely to see increased demand. This could be a key driver for Syngenta's long-term growth.
- Syngenta will leverage Ginkgo’s Ag Biologicals capabilities to optimize secondary metabolite production for a pioneering biological solution
Syngenta collaborates with Ginkgo Bioworks to enable faster launch of innovative biologicals. (Photo: Business Wire)
Through this new collaboration, Ginkgo plans to develop and optimize a microbial strain that can meet the productivity targets of a secondary metabolite from the Syngenta Biologicals pipeline. This molecule is earmarked by Syngenta as a pioneering biological solution. Successful cost-effective and large-scale production of this targeted metabolite would significantly expedite Syngenta's go-to-market timeline for its latest biological solution.
To achieve this, Ginkgo will use its Ag Biologicals capabilities to calculate theoretical performance and guide rational strain engineering strategies to develop the microbial strain that is robust enough to meet Syngenta’s goals. Ginkgo will leverage its biological knowledge and machine learning approaches to develop insights from multiple complex data sources and apply this toward diagnosing strain performance limitations as well as biological feature discovery.
“Biologicals are increasingly important in addressing the need for efficient and sustainable agricultural solutions worldwide. At Syngenta, we are committed to providing farmers with greater complementary product and technology choices that promote sustainable agricultural practices,” said Camilla Corsi, Global Head of Research at Syngenta Crop Protection. “We are excited to work with Ginkgo, and are confident that their distinctive capabilities will enable us to achieve our productivity goals for our targeted molecule, expediting our time to market.”
Magalie Guilhabert, Head of Ag Biologicals at Ginkgo Bioworks, said: “We are so excited to expand our relationship with Syngenta. We’ve built a successful relationship from our work together on plant traits and now look forward to doing the same with ag biologicals. Ginkgo is proud to put our excellent assets and experience against some of our customer’s toughest challenges. We’ll work to achieve productivity levels to realize commercial viability for Syngenta’s innovative ag biologicals product launch.”
About Syngenta Crop Protection
Syngenta Crop Protection is a leader in agricultural innovation, bringing breakthrough technologies and solutions that enable farmers to grow productively and sustainably. We offer a leading portfolio of crop protection solutions for plant and soil health, as well as digital solutions that transform the decision-making capabilities of farmers. Our 18,300 employees serve to advance agriculture in more than 90 countries around the world. Syngenta Crop Protection is headquartered in
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
To learn more about Ginkgo’s Ag Biologicals capabilities, please visit: https://www.ginkgobioworks.com/offerings/ag-biologicals-discovery-development/#production-strain-engineering
Syngenta’s Cautionary Statement Regarding Forward-Looking Statements
This document may contain forward-looking statements, which can be identified by terminology such as ‘expect’, ‘would’, ‘will’, ‘potential’, ‘plans’, ‘prospects’, ‘estimated’, ‘aiming’, ‘on track’ and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. For Syngenta, such risks and uncertainties include risks relating to legal proceedings, regulatory approvals, new product development, increasing competition, customer credit risk, general economic and market conditions, compliance and remediation, intellectual property rights, implementation of organizational changes, impairment of intangible assets, consumer perceptions of genetically modified crops and organisms or crop protection chemicals, climatic variations, fluctuations in exchange rates and/or commodity prices, single source supply arrangements, political uncertainty, natural disasters, and breaches of data security or other disruptions of information technology. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.
©2024 Syngenta. Rosentalstrasse 67, 4058
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) the outcome of any pending or potential legal proceedings against Ginkgo, (vii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (viii) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (ix) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's quarterly report on Form 10-Q filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716231883/en/
Gingko Bioworks Investor & Media contacts
investors@ginkgobioworks.com
press@ginkgobioworks.com
Source: Syngenta Crop Protection
FAQ
What is the purpose of the collaboration between Syngenta and Ginkgo Bioworks (DNA)?
How will Ginkgo Bioworks (DNA) contribute to the collaboration with Syngenta?
What is the potential impact of this collaboration on Syngenta's product launch timeline?
Have Syngenta and Ginkgo Bioworks (DNA) collaborated before?
